{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:32:51Z","timestamp":1791232371949,"version":"4.1.0"},"reference-count":122,"publisher":"SAGE Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2023,7,18]]},"abstract":"<jats:p>After the CLARITY-AD clinical trial results of lecanemab were interpreted as positive, and supporting the amyloid hypothesis, the drug received accelerated Food and Drug Administration approval. However, we argue that benefits of lecanemab treatment are uncertain and may yield net harm for some patients, and that the data do not support the amyloid hypothesis. We note potential biases from inclusion, unblinding, dropouts, and other issues. Given substantial adverse effects and subgroup heterogeneity, we conclude that lecanemab\u2019s efficacy is not clinically meaningful, consistent with numerous analyses suggesting that amyloid-\u03b2 and its derivatives are not the main causative agents of Alzheimer\u2019s disease dementia.<\/jats:p>","DOI":"10.3233\/jad-230099","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T10:21:32Z","timestamp":1686651692000},"page":"497-507","source":"Crossref","is-referenced-by-count":49,"title":["The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes"],"prefix":"10.1177","volume":"94","author":[{"given":"Kasper P.","family":"Kepp","sequence":"first","affiliation":[{"name":"Department of Chemistry, Section of Biophysical and Biomedicinal Chemistry, Technical University of Denmark, Kongens Lyngby, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano L.","family":"Sensi","sequence":"additional","affiliation":[{"name":"Center for Advanced Studies and Technology - CAST, and Institute for Advanced Biotechnology (ITAB), University G. d\u2019Annunzio of Chieti-Pescara, Italy"},{"name":"Department of Neuroscience, Imaging, and Clinical Sciences, University G. d\u2019Annunzio of Chieti-Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper B.","family":"Johnsen","sequence":"additional","affiliation":[{"name":"Department of Health Science and Technology, Neurobiology Research and Drug Delivery Group, Aalborg University, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge R.","family":"Barrio","sequence":"additional","affiliation":[{"name":"Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poul F.","family":"H\u00f8ilund-Carlsen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark"},{"name":"Department of Clinical Research, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael L.","family":"Neve","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abass","family":"Alavi","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Herrup","sequence":"additional","affiliation":[{"name":"Department of Neurobiology, University of Pittsburgh, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Perry","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Developmental and Regenerative Biology, The University of Texas at San Antonio, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos K.","family":"Robakis","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai Medical Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce","family":"Vissel","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Hospital Centre for Applied Medical Research, St Vincent\u2019s Hospital, Darlinghurst, NSW, Australia"},{"name":"School of Clinical Medicine, UNSW Medicine & Health, St Vincent\u2019s Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto J.","family":"Espay","sequence":"additional","affiliation":[{"name":"Department of Neurology, James J. and Joan A. Gardner Family Center for Parkinson\u2019s Disease and Movement Disorders, University of Cincinnati, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-230099_ref1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","article-title":"Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"GBD 2016 Dementia Collaborators","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-230099_ref2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","article-title":"Alzheimer\u2019s disease","volume":"368","author":"Blennow","year":"2015","journal-title":"Lancet"},{"key":"10.3233\/JAD-230099_ref3","doi-asserted-by":"crossref","first-page":"8729","DOI":"10.1073\/pnas.82.24.8729","article-title":"Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related","volume":"82","author":"Wong","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-230099_ref4","first-page":"253","article-title":"Amyloidosis in Alzheimer\u2019s disease and Down\u2019s syndrome","author":"Glenner","year":"1987","journal-title":"Molecular Neuropathology of Aging"},{"key":"10.3233\/JAD-230099_ref5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3233\/JAD-2006-9S317","article-title":"Alzheimer\u2019s disease: The amyloid cascade hypothesis - an update and reappraisal","volume":"9","author":"Hardy","year":"2006","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230099_ref6","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","article-title":"Amyloid plaque core protein in Alzheimer disease and Down syndrome","volume":"82","author":"Masters","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-230099_ref7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-230099_ref8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-230099_ref9","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-230099_ref10","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/alz.12379","article-title":"Bayes analysis supports null hypothesis of anti-amyloid beta therapy in Alzheimer\u2019s disease","volume":"17","author":"Richard","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230099_ref11","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-230099_ref12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41582-019-0295-9","article-title":"Questions EMERGE as Biogen claims aducanumab turnaround","volume":"16","author":"Howard","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-230099_ref13","doi-asserted-by":"crossref","first-page":"o2912","DOI":"10.1136\/bmj.o2912","article-title":"Lecanemab trial finds slight slowing of cognitive decline, but clinical benefits are uncertain","volume":"379","author":"Mahase","year":"2022","journal-title":"BMJ"},{"key":"10.3233\/JAD-230099_ref14","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1056\/NEJMc2109455","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"385","author":"Espay","year":"2021","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-230099_ref15","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/alz.12213","article-title":"Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019","volume":"17","author":"Knopman","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230099_ref16","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1001\/jama.2021.3854","article-title":"Evaluation of Aducanumab for Alzheimer disease: Scientific evidence and regulatory review involving efficacy, safety, and futility","volume":"325","author":"Alexander","year":"2021","journal-title":"JAMA"},{"key":"10.3233\/JAD-230099_ref17","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/S0140-6736(22)02480-1","article-title":"Lecanemab for Alzheimer\u2019s disease: Tempering hype and hope","volume":"400","author":"The Lancet","year":"2022","journal-title":"Lancet"},{"key":"10.3233\/JAD-230099_ref18","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1056\/NEJMp2110468","article-title":"Revisiting FDA approval of aducanumab","volume":"385","author":"Alexander","year":"2021","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-230099_ref19","first-page":"193","article-title":"Aducanumab trials EMERGE but don\u2019t ENGAGE","volume":"2022","author":"Schneider","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-230099_ref20","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","volume":"592","author":"Vogel","year":"2021","journal-title":"Nature"},{"key":"10.3233\/JAD-230099_ref21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-230099_ref22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","article-title":"Lecanemab, Aducanumab, and Gantenerumab \u2014 binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer\u2019s disease","volume":"20","author":"S\u00f6derberg","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.3233\/JAD-230099_ref23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-230099_ref24","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2967\/jnumed.113.120618","article-title":"Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2019s Association","volume":"54","author":"Johnson","year":"2013","journal-title":"J Nucl Med"},{"key":"10.3233\/JAD-230099_ref25","first-page":"135","article-title":"Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer\u2019s disease","volume":"2","author":"Morris","year":"2014","journal-title":"Acta Neuropathol Commun"},{"key":"10.3233\/JAD-230099_ref26","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00401-018-1918-8","article-title":"Questions concerning the role of amyloid-\u03b2 in the definition, aetiology and diagnosis of Alzheimer\u2019s disease","volume":"136","author":"Morris","year":"2018","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-230099_ref27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0166-2236(97)01168-5","article-title":"Alzheimer\u2019s disease: A re-examination of the amyloid hypothesis","volume":"21","author":"Neve","year":"1998","journal-title":"Trends Neurosci"},{"key":"10.3233\/JAD-230099_ref28","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1586\/ern.11.155","article-title":"Distinguishing Alzheimer\u2019s disease from other major forms of dementia","volume":"11","author":"Karantzoulis","year":"2011","journal-title":"Expert Rev Neurother"},{"key":"10.3233\/JAD-230099_ref29","doi-asserted-by":"crossref","first-page":"a006296","DOI":"10.1101\/cshperspect.a006296","article-title":"The genetics of Alzheimer disease","volume":"2","author":"Tanzi","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.3233\/JAD-230099_ref30","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.2174\/15680266113139990135","article-title":"The multifactorial nature of Alzheimer\u2019s disease for developing potential therapeutics","volume":"13","author":"Carreiras","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"10.3233\/JAD-230099_ref31","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer\u2019s disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-230099_ref32","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1038\/s41467-020-16876-4","article-title":"Cryo-EM structures of HKU2 and SADS-CoV spike glycoproteins provide insights into coronavirus evolution","volume":"11","author":"Yu","year":"2020","journal-title":"Nat Commun"},{"key":"10.3233\/JAD-230099_ref33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/nan.12101","article-title":"Review: The genetics of Alzheimer\u2019s disease; putting flesh on the bones","volume":"40","author":"Medway","year":"2014","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.3233\/JAD-230099_ref34","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1093\/hmg\/ddp406","article-title":"Genome-wide association studies in Alzheimer\u2019s disease","volume":"18","author":"Bertram","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.3233\/JAD-230099_ref35","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/gps.2628","article-title":"Alzheimer\u2019s disease genetics: Current knowledge and future challenges","volume":"26","author":"Hollingworth","year":"2011","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JAD-230099_ref36","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/ng.440","article-title":"Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer\u2019s disease","volume":"41","author":"Harold","year":"2009","journal-title":"Nat Genet"},{"key":"10.3233\/JAD-230099_ref37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.biopsych.2014.05.006","article-title":"Alzheimer\u2019s disease risk genes and mechanisms of disease pathogenesis","volume":"77","author":"Karch","year":"2015","journal-title":"Biol Psychiatry"},{"key":"10.3233\/JAD-230099_ref38","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10654-013-9794-y","article-title":"Midlife cardiovascular risk factors and late cognitive impairment","volume":"28","author":"Virta","year":"2013","journal-title":"Eur J Epidemiol"},{"key":"10.3233\/JAD-230099_ref39","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrendo.2009.168","article-title":"Obesity: Overweight as a risk factor for dementia","volume":"5","author":"Diaz","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"10.3233\/JAD-230099_ref40","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00401-015-1522-0","article-title":"Cerebrovascular disease in ageing and Alzheimer\u2019s disease","volume":"131","author":"Love","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-230099_ref41","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1159\/000330020","article-title":"Vascular risk factors and dementia: 40-year follow-up of a population-based cohort","volume":"31","author":"Ronnemaa","year":"2011","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JAD-230099_ref42","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jalz.2018.07.222","article-title":"Vascular dysfunction-the disregarded partner of Alzheimer\u2019s disease","volume":"15","author":"Sweeney","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230099_ref43","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","article-title":"Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing","volume":"51","author":"Kunkle","year":"2019","journal-title":"Nat Genet"},{"key":"10.3233\/JAD-230099_ref44","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/gim.2015.117","article-title":"The genetic landscape of Alzheimer disease: Clinical implications and perspectives","volume":"18","author":"Van Cauwenberghe","year":"2016","journal-title":"Genet Med"},{"key":"10.3233\/JAD-230099_ref45","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1212\/01.WNL.0000063311.58879.01","article-title":"Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer\u2019s disease","volume":"60","author":"Giannakopoulos","year":"2003","journal-title":"Neurology"},{"key":"10.3233\/JAD-230099_ref46","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.22248","article-title":"Longitudinal assessment of A\u03b2 and cognition in aging and Alzheimer disease","volume":"69","author":"Villemagne","year":"2011","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-230099_ref47","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.nurt.2008.05.001","article-title":"Therapeutics for Alzheimer\u2019s disease based on the metal hypothesis","volume":"5","author":"Bush","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.3233\/JAD-230099_ref48","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/ene.12761","article-title":"Regional \u03b2-amyloid burden does not correlate with cognitive or language deficits in Alzheimer\u2019s disease presenting as aphasia","volume":"23","author":"Jung","year":"2016","journal-title":"Eur J Neurol"},{"key":"10.3233\/JAD-230099_ref49","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/archneur.65.11.1509","article-title":"Frequent amyloid deposition without significant cognitive impairment among the elderly","volume":"65","author":"Aizenstein","year":"2008","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-230099_ref50","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1212\/01.wnl.0000219668.47116.e6","article-title":"Neuropathology of older persons without cognitive impairment from two community-based studies","volume":"66","author":"Bennett","year":"2006","journal-title":"Neurology"},{"key":"10.3233\/JAD-230099_ref51","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/j.neurobiolaging.2008.02.007","article-title":"CSF biomarker levels in early and late onset Alzheimer\u2019s disease","volume":"30","author":"Bouwman","year":"2009","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-230099_ref52","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00259-011-1960-4","article-title":"Amyloid-\u03b2 imaging with PET in Alzheimer\u2019s disease: Is it feasible with current radiotracers and technologies?","volume":"39","author":"Moghbel","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JAD-230099_ref53","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.3233\/JAD-215275","article-title":"Aducanumab (marketed as aduhelm) approval is likely based on misinterpretation of PET imaging data","volume":"84","author":"H\u00f8ilund-Carlsen","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230099_ref54","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3233\/JAD-130485","article-title":"Amyloid-\u03b2 positron emission tomography imaging probes: A critical review","volume":"36","author":"Kepe","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230099_ref55","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230099_ref56","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00259-019-04564-5","article-title":"Suboptimal validity of amyloid imaging-based diagnosis and management of Alzheimer\u2019s disease: Why it is time to abandon the approach","volume":"47","author":"Alavi","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JAD-230099_ref57","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3233\/JAD-180050","article-title":"Circular inference in dementia diagnostics","volume":"63","author":"H\u00f8ilund-Carlsen","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230099_ref58","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3233\/JAD-220841","article-title":"Amyloid PET: A questionable single primary surrogate efficacy measure on Alzheimer immunotherapy trials","volume":"90","author":"H\u00f8ilund-Carlsen","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230099_ref59","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1192\/bjp.140.6.566","article-title":"A new clinical scale for the staging of dementia","volume":"140","author":"Hughes","year":"1982","journal-title":"Br J Psychiatry"},{"key":"10.3233\/JAD-230099_ref60","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): Current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"key":"10.3233\/JAD-230099_ref61","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jalz.2011.01.005","article-title":"Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer\u2019s disease trials","volume":"7","author":"Coley","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230099_ref62","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1001\/archneur.65.8.1091","article-title":"Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: A Texas Alzheimer\u2019s research consortium study","volume":"65","author":"O\u2019Bryant","year":"2008","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-230099_ref63","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/gps.5436","article-title":"Diagnostic accuracy of the Clinical Dementia Rating Scale for detecting mild cognitive impairment and dementia: A bivariate meta-analysis","volume":"36","author":"Huang","year":"2021","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JAD-230099_ref64","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer\u2019s disease","volume":"141","author":"Rosen","year":"1984","journal-title":"Am J Psychiatry"},{"key":"10.3233\/JAD-230099_ref65","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00002093-199700112-00003","article-title":"Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer\u2019s Disease Assessment Scale that broaden its scope","volume":"11","author":"Mohs","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JAD-230099_ref66","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/alz.12286","article-title":"ENGAGE and EMERGE: Truth and consequences?","volume":"17","author":"Kuller","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230099_ref67","first-page":"9","article-title":"Establishing clinically meaningful change on outcome assessments frequently used in trials of mild cognitive impairment due to Alzheimer\u2019s disease","volume":"10","author":"Lansdall","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-230099_ref68","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.trci.2019.06.005","article-title":"Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer\u2019s disease clinical trials","volume":"5","author":"Andrews","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-230099_ref69","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/ene.14484","article-title":"Unblinded by the light: ARIA in Alzheimer\u2019s clinical trials","volume":"28","author":"Gleason","year":"2021","journal-title":"Eur J Neurol"},{"key":"10.3233\/JAD-230099_ref70","doi-asserted-by":"crossref","first-page":"e8668","DOI":"10.1136\/bmj.e8668","article-title":"Differential dropout and bias in randomised controlled trials: When it matters and when it may not","volume":"346","author":"Bell","year":"2013","journal-title":"BMJ"},{"key":"10.3233\/JAD-230099_ref71","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/ebmed-2017-110883","article-title":"Catalogue of bias: Attrition bias","volume":"23","author":"Nunan","year":"2018","journal-title":"BMJ Evid Based Med"},{"key":"10.3233\/JAD-230099_ref72","first-page":"93","article-title":"Handling drop-out in longitudinal clinical trials: A comparison of the LOCF and MMRM approaches","volume":"7","author":"Lane","year":"2008","journal-title":"Pharm Stat J Appl Stat Pharm Ind"},{"key":"10.3233\/JAD-230099_ref73","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/ana.10636","article-title":"Apolipoprotein E\u025b4 modifies Alzheimer\u2019s disease onset in an E280A PS1 kindred","volume":"54","author":"Pastor","year":"2003","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-230099_ref74","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.neuron.2017.11.013","article-title":"ApoE4 accelerates early seeding of amyloid pathology","volume":"96","author":"Liu","year":"2017","journal-title":"Neuron"},{"key":"10.3233\/JAD-230099_ref75","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archinte.158.9.1021","article-title":"Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study","volume":"158","author":"Rogers","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.3233\/JAD-230099_ref76","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1001\/archneur.61.12.1852","article-title":"Efficacy of donepezil in early-stage Alzheimer disease: A randomized placebo-controlled trial","volume":"61","author":"Seltzer","year":"2004","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-230099_ref77","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3233\/JAD-150448","article-title":"Changes in brain volume with Bapineuzumab in mild to moderate Alzheimer\u2019s disease","volume":"49","author":"Novak","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230099_ref78","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3233\/JAD-180105","article-title":"Stereological quantification of plaques and tangles in neocortex from Alzheimer\u2019s disease patients","volume":"64","author":"Madsen","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230099_ref79","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1073\/pnas.0330745100","article-title":"Amyloid deposition in the hippocampus and entorhinal cortex: Quantitative analysis of a transgenic mouse model","volume":"100","author":"Reilly","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-230099_ref80","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1148\/radiology.178.1.1984289","article-title":"Analysis of brain and cerebrospinal fluid volumes with MR imaging. Part I. Methods, reliability, and validation","volume":"178","author":"Kohn","year":"1991","journal-title":"Radiology"},{"key":"10.3233\/JAD-230099_ref81","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1148\/radiology.178.1.1984290","article-title":"Analysis of brain and cerebrospinal fluid volumes with MR imaging: Impact on PET data correction for atrophy. Part II. Aging and Alzheimer dementia","volume":"178","author":"Tanna","year":"1991","journal-title":"Radiology"},{"key":"10.3233\/JAD-230099_ref82","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/j.semnuclmed.2006.10.002","article-title":"Structural and functional imaging correlates for age-related changes in the brain","volume":"37","author":"Tumeh","year":"2007","journal-title":"Semin Nucl Med"},{"key":"10.3233\/JAD-230099_ref83","doi-asserted-by":"crossref","first-page":"e2144","DOI":"10.1212\/WNL.0000000000207156","article-title":"Accelerated brain volume loss caused by anti-\u03b2-amyloid drugs: A systematic review and meta-analysis","volume":"100","author":"Alves","year":"2023","journal-title":"Neurology"},{"key":"10.3233\/JAD-230099_ref84","unstructured":"Christensen J (2022) Experimental Alzheimer\u2019s drug may have contributed to death of study participant, according to reports. CNN. https:\/\/edition.cnn.com\/2022\/10\/28\/health\/alzheimers-drug-lecanemab-trial\/index.html"},{"key":"10.3233\/JAD-230099_ref85","unstructured":"Piller C (2022) Second death linked to potential antibody treatment for Alzheimer\u2019s disease. Science. https:\/\/www.science.org\/content\/article\/second-death-linked-potential-antibody-treatment-alzheimer-s-disease"},{"key":"10.3233\/JAD-230099_ref86","unstructured":"Piller C (2022) Scientists tie third clinical trial death to experimental Alzheimer\u2019s drug. Science. https:\/\/www.science.org\/content\/article\/scientists-tie-third-clinical-trial-death-experimental-alzheimer-s-drug"},{"key":"10.3233\/JAD-230099_ref87","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5853\/jos.2015.17.1.17","article-title":"Cerebral amyloid angiopathy: Emerging concepts","volume":"17","author":"Yamada","year":"2015","journal-title":"J Stroke"},{"key":"10.3233\/JAD-230099_ref88","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-230099_ref89","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: A retrospective analysis","volume":"11","author":"Sperling","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-230099_ref90","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/1570159X15666170116143743","article-title":"The amyloid cascade hypothesis in Alzheimer\u2019s disease: It\u2019s time to change our mind","volume":"15","author":"Ricciarelli","year":"2017","journal-title":"Curr Neuropharmacol"},{"key":"10.3233\/JAD-230099_ref91","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1749-6632.2000.tb05557.x","article-title":"Arson. Tracking the culprit in Alzheimer\u2019s disease","volume":"924","author":"Smith","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"10.3233\/JAD-230099_ref92","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/S0891-5849(02)01021-3","article-title":"Amyloid-\u03b2 and \u03c4 serve antioxidant functions in the aging and Alzheimer brain","volume":"33","author":"Smith","year":"2002","journal-title":"Free Radic Biol Med"},{"key":"10.3233\/JAD-230099_ref93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1297.001","article-title":"Challenging the amyloid cascade hypothesis: Senile plaques and amyloid-\u03b2 as protective adaptations to Alzheimer disease","volume":"1019","author":"Lee","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"10.3233\/JAD-230099_ref94","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/ng1943","article-title":"The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease","volume":"39","author":"Rogaeva","year":"2007","journal-title":"Nat Genet"},{"key":"10.3233\/JAD-230099_ref95","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/j.neurobiolaging.2014.03.033","article-title":"Dietary and lifestyle guidelines for the prevention of Alzheimer\u2019s disease","volume":"35","author":"Barnard","year":"2014","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-230099_ref96","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.febslet.2013.12.038","article-title":"The dark sides of amyloid in Alzheimer\u2019s disease pathogenesis","volume":"588","author":"Sorrentino","year":"2014","journal-title":"FEBS Lett"},{"key":"10.3233\/JAD-230099_ref97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1192\/bjp.bp.115.167569","article-title":"Alzheimer\u2019s disease: The amyloid hypothesis on trial","volume":"208","author":"Harrison","year":"2016","journal-title":"Br J Psychiatry"},{"key":"10.3233\/JAD-230099_ref98","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3233\/JAD-160550","article-title":"Ten challenges of the amyloid hypothesis of Alzheimer\u2019s disease","volume":"55","author":"Kepp","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230099_ref99","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.neurobiolaging.2010.05.022","article-title":"Mechanisms of AD neurodegeneration may be independent of Abeta and its derivatives","volume":"32","author":"Robakis","year":"2011","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-230099_ref100","first-page":"E476","article-title":"Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of A\u03b242 and A\u03b240 peptides by \u03b3-secretase","volume":"114","author":"Sun","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-230099_ref101","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jalz.2015.06.1895","article-title":"\u03b2-amyloid pathogenesis: Chemical properties versus cellular levels","volume":"12","author":"Tiwari","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230099_ref102","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/sj.emboj.7601031","article-title":"Metalloproteinase\/Presenilin1 processing of ephrinB regulates EphB-induced Src phosphorylation and signaling","volume":"25","author":"Georgakopoulos","year":"2006","journal-title":"EMBO J"},{"key":"10.3233\/JAD-230099_ref103","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.celrep.2013.10.018","article-title":"The Presenilin-1 \u03b4E9 mutation results in reduced \u03b3-secretase activity, but not total loss of PS1 function, in isogenic human stem cells","volume":"5","author":"Woodruff","year":"2013","journal-title":"Cell Rep"},{"key":"10.3233\/JAD-230099_ref104","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1471-4159.2006.04391.x","article-title":"FAD mutants unable to increase neurotoxic A\u03b242 suggest that mutation effects on neurodegeneration may be independent of effects on Abeta","volume":"101","author":"Shioi","year":"2007","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-230099_ref105","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1073\/pnas.0608332104","article-title":"The presenilin hypothesis of Alzheimer\u2019s disease: Evidence for a loss-of-function pathogenic mechanism","volume":"104","author":"Shen","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-230099_ref106","doi-asserted-by":"crossref","first-page":"e1556","DOI":"10.1002\/wcms.1556","article-title":"Understanding familial Alzheimer\u2019s disease: The fit-stay-trim mechanism of \u03b3-secretase","volume":"12","author":"Mehra","year":"2022","journal-title":"Wiley Interdiscip Rev Comput Mol Sci"},{"key":"10.3233\/JAD-230099_ref107","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1021\/acschemneuro.7b00208","article-title":"Membrane dynamics of \u03b3-Secretase provides a molecular basis for \u03b2-amyloid binding and processing","volume":"8","author":"Somavarapu","year":"2017","journal-title":"ACS Chem Neurosci"},{"key":"10.3233\/JAD-230099_ref108","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/jnc.13535","article-title":"Loss of stability and hydrophobicity of presenilin 1 mutations causing Alzheimer\u2019s disease","volume":"137","author":"Somavarapu","year":"2016","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-230099_ref109","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/nn.4017","article-title":"The case for rejecting the amyloid cascade hypothesis","volume":"18","author":"Herrup","year":"2015","journal-title":"Nat Neurosci"},{"key":"10.3233\/JAD-230099_ref110","doi-asserted-by":"crossref","first-page":"32730","DOI":"10.1074\/jbc.273.49.32730","article-title":"Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation","volume":"273","author":"Qiu","year":"1998","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-230099_ref111","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3233\/JAD-2010-1206","article-title":"Insulin-degrading enzyme sorting in exosomes: A secretory pathway for a key brain amyloid-\u03b2 degrading protease","volume":"19","author":"Bulloj","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230099_ref112","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1073\/pnas.0230450100","article-title":"Insulin-degrading enzyme regulates the levels of insulin, amyloid \u03b2-protein, and the \u03b2-amyloid precursor protein intracellular domain in vivo","volume":"100","author":"Farris","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-230099_ref113","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ccr.2013.10.008","article-title":"The clearance of misfolded proteins in neurodegenerative diseases by zinc metalloproteases: An inorganic perspective","volume":"260","author":"Malgieri","year":"2014","journal-title":"Coord Chem Rev"},{"key":"10.3233\/JAD-230099_ref114","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1097\/NEN.0b013e3182345e46","article-title":"Abeta-degrading enzymes: Potential for treatment of Alzheimer disease","volume":"70","author":"Miners","year":"2011","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-230099_ref115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1471-4159.2002.00855.x","article-title":"\u03b2-Amyloid catabolism: Roles for neprilysin (NEP) and other metallopeptidases?","volume":"81","author":"Carson","year":"2002","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-230099_ref116","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.bcp.2018.09.026","article-title":"Alzheimer\u2019s disease (AD) therapeutics \u2013 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality","volume":"158","author":"Mullane","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.3233\/JAD-230099_ref117","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-related imaging abnormalities in 2 Phase 3 studies evaluating Aducanumab in patients with early Alzheimer disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-230099_ref118","doi-asserted-by":"crossref","first-page":"10582","DOI":"10.1523\/JNEUROSCI.1736-09.2009","article-title":"\u03b2-amyloid monomers are neuroprotective","volume":"29","author":"Giuffrida","year":"2009","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-230099_ref119","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jalz.2018.03.005","article-title":"Estimation of lifetime risks of Alzheimer\u2019s disease dementia using biomarkers for preclinical disease","volume":"14","author":"Brookmeyer","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230099_ref120","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1001\/jamaneurol.2019.1971","article-title":"Prevalence of biologically vs clinically defined Alzheimer spectrum entities using the National Institute on Aging-Alzheimer\u2019s Association Research Framework","volume":"76","author":"Jack","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-230099_ref121","doi-asserted-by":"crossref","first-page":"100988","DOI":"10.1016\/j.eclinm.2021.100988","article-title":"High cerebrospinal amyloid-\u03b2 42 is associated with normal cognition in individuals with brain amyloidosis","volume":"38","author":"Sturchio","year":"2021","journal-title":"eClinicalMedicine"},{"key":"10.3233\/JAD-230099_ref122","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3233\/JAD-220808","article-title":"High soluble amyloid-\u03b2 42 predicts normal cognition in amyloid-positive individuals with Alzheimer\u2019s disease-causing mutations","volume":"90","author":"Sturchio","year":"2022","journal-title":"J Alzheimers Dis"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-230099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:07:56Z","timestamp":1777370876000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-230099"}},"subtitle":[],"editor":[{"given":"Paula","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":122,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jad-230099","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]}}}